Posaconazole tablet pharmacokinetics: Lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4020-4025

  Kraft, Walter K ^a   Chang, Peter S ^a   Van Iersel, Marlou L P S ^b   Waskin, Hetty ^c   Krishna, Gopal ^c,d   Kersemaekers, Wendy M ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MSD   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ESOMEPRAZOLE; MAGNESIUM; METOCLOPRAMIDE; POSACONAZOLE; RANITIDINE; ANTACID AGENT; ANTIFUNGAL AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; TABLET; TRIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH MOTILITY; STOMACH PH; TABLET; YOUNG ADULT; DRUG INTERACTION; GASTROINTESTINAL MOTILITY; PH; PHYSIOLOGY; STOMACH ACID;

ADULT; ANTACIDS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; GASTRIC ACID; GASTROINTESTINAL MOTILITY; HEALTHY VOLUNTEERS; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TABLETS; TRIAZOLES; YOUNG ADULT;

EID: 84903125981     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02448-13     Document Type: Article

References (20)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094. (Pubitemid 46148777)
2. Keating GM. 2005. Posaconazole. Drugs 65:1553-1567. http://dx.doi.org/10. 2165/00003495-200565110-00007. (Pubitemid 41124308)
3. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. 2006. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403. http://dx.doi.org/10.1086/503425.
4. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10. 1056/NEJMoa061098. (Pubitemid 46148776)
5. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JAH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086/508774. (Pubitemid 44968977)
6. Merck & Co. 2012. Noxafil (posaconazole) oral suspension prescribing information. Merck & Co., Whitehouse Station, NJ.
7. Merck Sharp & Dohme Limited. 2012. Noxafil (posaconazole) oral suspension, summary of product characteristics. Merck Sharp & Dohme Limited, Hertfordshire, United Kingdom.
8. AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26:397-405. http://dx.doi.org/10.1185/03007990903485056.
9. Courtney R, Pai S, Laughlin M, Lim J, Batra V. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47: 2788-2795. http://dx.doi.org/10.1128/AAC.47.9.2788-2795.2003. (Pubitemid 37040249)
10. Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752. http://dx.doi.org/10.1128/AAC.00889-09.
11. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627. (Pubitemid 350234311)
12. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
13. Krishna G, Tarif MA, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.
14. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50:1881-1883. http://dx.doi.org/10. 1128/AAC.50.5.1881-1883.2006.
15. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. http://dx.doi.org/10.1128/AAC.50.2. 658-666.2006. (Pubitemid 43190980)
16. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222. http://dx.doi.org/10.1046/ j.1365-2125.2003.01977.x. (Pubitemid 38223535)
17. Pille S, Bohmer D. 1998. Options for artificial nutrition of cancer patients. Strahlenther. Onkol. 174(suppl 3):52-55. (Pubitemid 28506594)
18. Vehreschild MJ, Meissner AM, Cornely OA, Maschmeyer G, Neumann S, Von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ. 2011. Clinically defined chemotherapyassociated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 96:1855-1860. http://dx.doi.org/10.3324/haematol.2011.049627.
19. Krishna G, Ma L, Martinho M, O'Mara E. 2012. A single dose phase I study to evaluate the pharmacokinetics of posaconazole new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196-4201. http://dx.doi.org/10.1128/AAC.00222-12.
20. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236. http://dx.doi.org/10.1016/j.jpba.2006.06. 011. (Pubitemid 44856187)